Clinical Trial

Preventing Posttraumatic Joint contractuRes with Ketotifen 2

Study Description

PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK 2) is a Phase III randomized, controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg or lactose placebo twice daily orally for 6 weeks) and a primary endpoint of elbow extension-flexion range of motion (ROM) arc at 12 weeks post-randomization.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Lactose Placebo

One capsule by mouth twice per day

Drug - Ketotifen Fumarate 2mg

2 mg tablets (over-encapsulated into one capsule) by mouth twice per day

Drug - Ketotifen Fumarate 5mg

5 mg tablets (over-encapsulated into one capsule) by mouth twice per day

Additional Information

Official Study Title

PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

Clinical Trial ID

NCT03582176

ParticipAid ID

eXDxge